Cortech, SmithKline deal

The companies entered into a development and license agreement for CRTQ's Bradycor bradykinin antagonist to treat traumatic brain injury (TBI) and other indications including ischemic stroke.

SmithKline (Philadelphia) will pay future development costs and will make license and milestone payments of up to $25 million if the drug is approved for marketing for TBI and ischemic stroke. CRTQ (Denver) will receive royalties. ...